Publications

  1. von Roemeling CA, Marlow LA, Wei JJ, Cooper SJ, Caulfield TR, Wu K, Tan WW, Tun HW, Copland JA. Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma. Clin Cancer Res. 2013 May 1; 19(9):2368-80. Epub 2013 Apr 30. 2320450
    View PubMed
  2. Tan W. Reply. Urology. 2013 Jan; 81(1):154. 2292423
    View PubMed
  3. Tan WW, Heckman MG, Vishnu P, Crook JE, Younkin LH, Covil EG, Ferman TJ, Graff-Radford NR, Younkin SG, Smallridge RC, Wehle MJ, Buskirk SJ. Effect of leuprolide on serum amyloid-beta peptide levels and memory in patients with prostate cancer with biochemical recurrence. Urology. 2013 Jan; 81(1):150-4. 2292432
    View PubMed
  4. Ahmad A, Wu K, Tan WW. Renal Cell Carcinoma with Skin metastasis: A Case Report and Literature Review. Cancer and Clinical Oncology. 01/2013; 2(1):1-7. 2289066
  5. Andhavaradrapu S, Tan WW. Practical insights and challenges in the rational use of targeted agents in metastatic clear cell renal carcinoma. Cancer and Clinical Oncology. 2012 May; 125(1361):102-104 Epub 2012. 2226010
  6. Tan WW, Allred JB, Salim M, Flynn P, Fishkin PA, Stella PJ, Wiesenfeld M, Bernath AM, Fitch TR, Perez EA. Phase II interventional study (N0337) of capecitabine in combination with vinorelbine and trastuzumab for first- or second-line treatment of HER2-positive metastatic breast cancer: a north central cancer treatment group trial. Clin Breast Cancer. 2012 Apr; 12(2):81-6. 2235300
    View PubMed
  7. Finn L, Tan W. Proof of concept to clinical confirmation: evolving clinical trial designs for targeted agents. ISRN Oncol. 2012; 2012:478607. Epub 2012 Jun 3. 2252646
    View PubMed
  8. Ahmad A, Tan WW. Castrate Resistant Metastatic Prostate Cancer: Options for a Patient in 2012. Open Journal Urology. 2012; 2:210-215 Epub 2012 Oct. 2268061
  9. Ahmad A, Tan W. Atypical Presentation of Prostate Cancer and workup of an adenocarcinoma of Unknown primary. World J Urol. 2012(3(4)):187-190. 2266255
  10. Andhavarapu S, Tan WW. Medical image. papules of unknown aetiology. Disseminated Curvularia. N Z Med J. 2012; 125(1361):102-4. Epub 2012 Sep 07. 2276565
    View PubMed
  11. Ames SC, Parker AS, Crook JE, Diehl NN, Tan WW, Williams CR, Ames GE. Quality of life of patients undergoing surgical treatment for newly-diagnosed, clinically localized renal cell carcinoma. J Psychosoc Oncol. 2011 Nov; 29(6):593-605. 2184315
    View PubMed
  12. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD Jr, Crook JE, Williams CR, Werch CE, Clark MM, Rummans TA. A pilot investigation of a multidisciplinary quality of life intervention for men with biochemical recurrence of prostate cancer. Psychooncology. 2011 Apr; 20(4):435-40. Epub 2010 May 24. 2116220
    View PubMed
  13. Tzou K, Tan WW, Buskirk S. Treatment of men with rising prostate-specific antigen levels following radical prostatectomy. Expert Rev Anticancer Ther. 2011 Jan; 11(1):125-36. 2136032
    View PubMed
  14. Vishnu P, Mathew J, Tan WW. Current therapeutic strategies for invasive and metastatic bladder cancer. Onco Targets Ther. 2011; 4:97-113. Epub 2011 Jul 11. 2179432
    View PubMed
  15. Tan WW, Hillman DW, Salim M, Northfelt DW, Anderson DM, Stella PJ, Niedringhaus R, Bernath AM, Gamini SS, Palmieri F, Perez EA. N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial. Ann Oncol. 2010 Mar; 21(3):493-7. Epub 2009 Jul 22. 1953746
    View PubMed
  16. Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA. Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist. 2010; 15(10):1043-9. Epub 2010 Oct 07. 2119082
    View PubMed
  17. Vishnu P, Tan WW. Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther. 2010; 3:39-51. Epub 2010 Jun 24. 2105096
    View PubMed
  18. Tan W, Hillman D, Salim M, Northfelt D, Anderson D, Stella P, Niedringhaus R, Bernath, Jr. A, Gamini S, Palmieri F, Perez E N0332 Phase 2 Trial of Weekly Irinotecan Hydrochloride and Docetaxel in Refractory Metastatic Breast Cancer: A North Central Cancer Treatment Group (NCCTG) Trial Ann Oncol. 2009:(Published On-LIne). 2011011
    View PubMed
  19. Moss JE, Tan WW, Menke DM, Johnson MM. Multiple pulmonary nodules in an asymptomatic man. The Journal of Medicine. 2009; 2(4):205-10. 1990978
  20. Hines S, Tan WW, Moreno A, Roy V, Vallow L, Mclaughlin S, Perez, E. A practical Clinical appraoch to Adjuvant Therapy in Breast Cancer- An update. US Oncological Review. 2009; 5 (1):49-53. 2188781
  21. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, Harper F, Gaskins M, Pitot HC, Tan W, Ivy SP, Pili R, Carducci MA, Erlichman C, Liu G. A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res. 2008 Dec 1; 14(23):7940-6. 1908849
    View PubMed
  22. Hines SL, Vallow LA, Tan WW, McNeil RB, Perez EA, Jain A. Clinical outcomes after a diagnosis of brain metastases in patients with estrogen- and/or human epidermal growth factor receptor 2-positive versus triple-negative breast cancer. Ann Oncol. 2008 Sep; 19(9):1561-5. Epub 2008 Jun 05. 1904705
    View PubMed
  23. Coe SG, Tan WW, Fox TP. Cushing's syndrome due to ectopic adrenocorticotropic hormone production secondary to hepatic carcinoid: diagnosis, treatment, and improved quality of life. J Gen Intern Med. 2008 Jun; 23(6):875-8. Epub 2008 Apr 02. 1891540
    View PubMed
  24. Hines SL, Tan W, Larson JM, Thompson KM, Jorn HK, Files JA. A practical approach to guide clinicians in the evaluation of male patients with breast masses. Geriatrics. 2008 Jun; 63(6):19-24. 1888421
    View PubMed
  25. Ames SC, Tan WW, Ames GE, Stone RL, Rizzo TD Jr, Heckman MG, Crook JE, Clark MM, Rummans TA, Werch CE. Quality of life of men with biochemical recurrence of prostate cancer. J Psychosoc Oncol. 2008; 26(2):17-34. 1883063
    View PubMed
  26. Pendleton JM, Tan WW, Anai S, Chang M, Hou W, Shiverick KT, Rosser CJ. Phase II trial of isoflavone in prostate-specific antigen recurrent prostate cancer after previous local therapy. BMC Cancer. 2008; 8:132. Epub 2008 May 11. 1909341
    View PubMed
  27. Tan W. [Promising new treatment options for metastatic androgen-independent prostate cancer]. Actas Urol Esp. 2007 Jun; 31(6):680-5. 1853544
    View PubMed
  28. Hines SL, Tan WW, Yasrebi M, DePeri ER, Perez EA. The role of mammography in male patients with breast symptoms. Mayo Clin Proc. 2007 Mar; 82(3):297-300. 1812276
    View PubMed
  29. Jatoi A, Burch P, Hillman D, Vanyo JM, Dakhil S, Nikcevich D, Rowland K, Morton R, Flynn PJ, Young C, Tan W, North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. Urology. 2007 Feb; 69(2):289-94. 2240797
    View PubMed
  30. Lee S, Desai KK, Iczkowski KA, Newcomer RG, Wu KJ, Zhao YG, Tan WW, Roycik MD, Sang QX. Coordinated peak expression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res. 2006 Sep; 16(9):750-8. 1789420
    View PubMed
  31. Tan WW. Novel agents and targets in managing patients with metastatic prostate cancer. Cancer Control. 2006 Jul; 13(3):194-8. 1796793
    View PubMed
  32. Hughes CL, Tan WW, Ferrone M. Sorafenib for the treatment of renal cell carcinoma. J Pharm Technol. 2006; 22(5):281-8. 1972009
    View PubMed
  33. Heath EI, Gaskins M, Pitot HC, Pili R, Tan W, Marschke R, Liu G, Hillman D, Sarkar F, Sheng S, Erlichman C, Ivy P. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Prostate Cancer. 2005 Sep; 4(2):138-41. 2121309
    View PubMed
  34. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs. 2005 Jun; 23(3):257-61. 1716377
    View PubMed
  35. Tan M, Tan W. Polypharmacy in the Elders.(CME article) Federal Practitioner. 2005; 22(11):76-88. 1685263
  36. Baweja M, Tan W. Bone metastases from Prostate cancer: Known and Novel targets for palliation. Palliative and Supportive Cancer care Journal. 2005; 1(2):47-58. 1662647
    View PubMed
  37. Mincey BA, Tan W. The management of bone loss in patients with breast or prostate cancer. Support Cancer Therapy. 2004; 1(3):1-7. 1642126
    View PubMed
  38. Tan M, Tan W. Osteoporosis in prostate cancer(CME Article). Federal Practitioner. 2004; 21(12):72-79. 1642130
  39. Jatoi A, Ellison N, Burch PA, Sloan JA, Dakhil SR, Novotny P, Tan W, Fitch TR, Rowland KM, Young CY, Flynn PJ. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer. 2003 Mar 15; 97(6):1442-6. 1319008
    View PubMed
  40. Tan WW, Walsh T. Ocular toxicity secondary to paclitaxel in two lung cancer patients. Medical & Pediatric Oncology. 1998 Sep; 31(3):177. 1414814
    View PubMed
  41. Tan W, Herzlich BC, Funaro R, Koutelos K, Pagala M, Amaladevi B, Grob D. Rhabdomyolysis and myoglobinuric acute renal failure associated with classic heat stroke. South Med J. 1995 Oct; 88(10):1065-8. 1414764
    View PubMed
  42. Tan W, Chapnick E, Abter EIM, et al. Paromomycin associated pancreatitis in HIV related cryptosoridiosis. Ann Pharmacother. 1995; 29:22-3. 1414774
    View PubMed
  43. Tan W, Schiano TD, Moss D, Herzlich BC. Hepatic artery aneurysm associated with acute gastroenteritis: successful treatment after intraperitoneal rupture. South Med J. 1994 Aug; 87(8):831-2. 1414748
    View PubMed
  44. Tan W, Chua M. Hemolytic anemia in SLE. The Philippine Journal of Pediatrics. 1989; 38(4):255-8. 1414697